These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 9762948)

  • 1. A Phase I study of granulocyte-macrophage-colony stimulating factor/interleukin-3 fusion protein (PIXY321) following ifosfamide, carboplatin, and etoposide therapy for children with recurrent or refractory solid tumors: a report of the Children's Cancer Group.
    Cairo MS; Krailo MD; Weinthal JA; Secola R; Bergeron S; van de Ven C; Blazar BR; Garrison L; Reaman GH
    Cancer; 1998 Oct; 83(7):1449-60. PubMed ID: 9762948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience.
    Angiolillo AL; Davenport V; Bonilla MA; van de Ven C; Ayello J; Militano O; Miller LL; Krailo M; Reaman G; Cairo MS;
    Clin Cancer Res; 2005 Apr; 11(7):2644-50. PubMed ID: 15814645
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy.
    Furman WL; Rodman JH; Tonda ME; Luo X; Arnold B; Marina N; Garrison L; Hanna R; Pratt CB; Meyer WH
    Cancer Chemother Pharmacol; 1998; 41(3):229-36. PubMed ID: 9443640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical, pharmacological, and biological trial of interleukin 6 plus granulocyte-colony stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent/refractory solid tumors: enhanced hematological responses but a high incidence of grade III/IV constitutional toxicities.
    Bracho F; Krailo MD; Shen V; Bergeron S; Davenport V; Liu-Mares W; Blazar BR; Panoskaltsis-Mortari A; van de Ven C; Secola R; Ames MM; Reid JM; Reaman GH; Cairo MS
    Clin Cancer Res; 2001 Jan; 7(1):58-67. PubMed ID: 11205919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.
    Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS
    Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
    Crawford J; George M
    Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of high-dose etoposide/ifosfamide/carboplatin/epirubicin and peripheral blood progenitor cell transplantation in limited-disease small cell lung cancer.
    Brugger W; Frommhold H; Pressler K; Mertelsmann R; Kanz L
    Semin Oncol; 1995 Feb; 22(1 Suppl 2):3-8. PubMed ID: 7531368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
    Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
    Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
    Murren JR; Gollerkeri A; Anderson S; Lutzker S; Del Prete S; Zelterman D; Garrison L; Smith B
    Yale J Biol Med; 1998; 71(5):355-65. PubMed ID: 10527363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a children's cancer group report.
    Cairo MS; Shen V; Krailo MD; Bauer M; Miser JS; Sato JK; Blatt J; Blazar BR; Frierdich S; Liu-Mares W; Reaman GH
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):30-8. PubMed ID: 11196267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer.
    Takahashi M; Yoshizawa H; Tanaka H; Tanaka J; Kagamu H; Ito K; Shimbo T; Chou D; Wakabayashi M; Suzuki E; Sakai K; Arakawa M; Gejyo F
    Bone Marrow Transplant; 2000 Jan; 25(1):5-11. PubMed ID: 10654007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ifosfamide, carboplatin, etoposide, and paclitaxel chemotherapy: a dose-escalation study.
    Chang AY; Boros L; Garrow GC; Asbury RF; Hui L
    Semin Oncol; 1996 Jun; 23(3 Suppl 6):74-7. PubMed ID: 8677454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-intensive ifosfamide/carboplatin/etoposide plus granulocyte-macrophage colony-stimulating factor for non-small cell lung cancer.
    Palackdharry CS; Krigel RL
    Semin Oncol; 1994 Jun; 21(3 Suppl 4):6-11. PubMed ID: 8209278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S; Kirsch A; Schwaner I; Kingreen D; Schwella N; Huhn D; Siegert W
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose ifosfamide/carboplatin/etoposide with autologous hematopoietic stem cell support: safety and future directions.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; McCauley M; Mazanet R; Schnipper L; Frei E; Antman KH
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):83-5. PubMed ID: 7992072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma.
    Miniero R; Brach del Prever A; Vassallo E; Nesi F; Busca A; Fagioli F; Albiani R; Picci P; Bacci G; Madon E
    Bone Marrow Transplant; 1998 Dec; 22 Suppl 5():S37-40. PubMed ID: 9989888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
    Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.